ESR1 and breast neoplasm: Since these pathways has been associated not only with higher proliferation but also with TAM resistance [50], the evaluation of AR expression in breast tumors, could help to detect a subset of cases possibly AR-driven, as suggested by the AR-ness signature on cases with AR/ER ratio ≥ 2 (Figure 4), which would benefit from anti-AR tailored therapies.